Suven Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 543064 | NSE: SUVENPHAR | Pharmaceuticals & Drugs | Small Cap

Suven Pharma Share Price

1,272.05 -7.45 -0.58%
as on 21-Nov'24 13:56

DeciZen - make an informed investing decision on Suven Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Suven Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (CD):
133.98
Market Cap:
32,571.6 Cr.
52-wk low:
578.1
52-wk high:
1,358.8

Is Suven Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Suven Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Suven Pharmaceuticals Ltd is a good quality company.

2. Is Suven Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Suven Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Suven Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Suven Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Suven Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Suven Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 0%0%0%0%23.9%50.2%40.8%45.9%33.4%21.2%-
Value Creation
Index
NANANANA1.13.52.02.41.50.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 00003788341,0101,3201,3401,051961
Sales YoY Gr.-NANANANA120.7%21.1%30.8%1.5%-21.6%-
Adj EPS 000001213.915.315.110.39.6
YoY Gr.-NANANANANA15.9%10.5%-1.2%-31.7%-
BVPS (₹) 0000033.246.46068.280.577.7
Adj Net
Profit
0000111305353390385263243
Cash Flow from Ops. 000050.4407383330457358-
Debt/CF from Ops. 00001.60.50.40.30.20.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA22.7%1.4%-21.6%
Adj EPS NANA-9.4%-31.7%
BVPSNANA20.2%18.1%
Share Price - - 35.8% 112.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
000018.842.534.928.823.613.912.1
Op. Profit
Mgn %
000046.146.243.944.142.838.633.6
Net Profit
Mgn %
000029.436.63529.628.82525.3
Debt to
Equity
00000.10.20.10.1000
Working Cap
Days
00000196175172195213214
Cash Conv.
Cycle
0000081576989104184

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 12.10%

Sales growth has been subdued in last 3 years 1.36%

Net Profit has been subdued in last 3 years -9.35%

Sales growth is not so good in last 4 quarters at -22.87%

Latest Financials - Suven Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 9.7 9.6
TTM Sales (₹ Cr.) 915 961
BVPS (₹.) 86.7 77.7
Reserves (₹ Cr.) 2,181 1,953
P/BV 14.76 16.46
PE 131.76 133.98
From the Market
52 Week Low / High (₹) 578.05 / 1358.75
All Time Low / High (₹) 87.05 / 1358.75
Market Cap (₹ Cr.) 32,572
Equity (₹ Cr.) 25.5
Face Value (₹) 1
Industry PE 43

Management X-Ray of Suven Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Suven Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales3788341,0101,3201,3401,051
Operating Expenses 206449567739766646
Manufacturing Costs53122150189184137
Material Costs101225298394403311
Employee Cost 306576100118136
Other Costs 223643556161
Operating Profit 172385443582574406
Operating Profit Margin (%) 45.4%46.1%43.9%44.1%42.8%38.6%
Other Income 11814924662
Interest 323129137
Depreciation 112432394855
Exceptional Items 000000
Profit Before Tax 158405468668560406
Tax 4988105214148105
Profit After Tax 109317362454411300
PAT Margin (%) 28.9%38.0%35.9%34.4%30.7%28.6%
Adjusted EPS (₹)0.012.514.217.816.211.8
Dividend Payout Ratio (%)0%20%14%28%37%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 5788451,1811,5271,7352,049
Share Capital 01325252525
Reserves 5788321,1551,5021,7102,023
Minority Interest000000
Debt83185141966939
Long Term Debt091362850
Short Term Debt8394106676539
Trade Payables5471831067042
Others Liabilities 102191171238236224
Total Liabilities 8161,2921,5761,9672,1102,353

Fixed Assets

Gross Block347457570694876927
Accumulated Depreciation77100128160212258
Net Fixed Assets271357441534663670
CWIP 1111029630165179
Investments 7338542598536904
Inventories157175201283313231
Trade Receivables148117102236111134
Cash Equivalents 131410476850
Others Assets109190184237254185
Total Assets 8161,2921,5761,9672,1102,353

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 50407383330457358
PBT 158405468668560406
Adjustment 143536413715
Changes in Working Capital -8854-12-194647
Tax Paid -33-86-109-184-146-110
Cash Flow From Investing Activity -65-413-311-136-195-362
Capex -57-103-111-75-286-52
Net Investments -7-325-201-30084-312
Others -215023962
Cash Flow From Financing Activity 267-76-156-242-14
Net Proceeds from Shares 000000
Net Proceeds from Borrowing 5291-55-10-24-5
Interest Paid -3-17-9-6-12-7
Dividend Paid -19-64-25-102-2040
Others -4-313-39-3-2
Net Cash Flow 111-53720-18
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)18.9244.5835.7833.5225.2115.87
ROCE (%)23.8750.2140.7645.9233.4121.22
Asset Turnover Ratio0.460.790.70.750.660.47
PAT to CFO Conversion(x)0.461.281.060.731.111.19
Working Capital Days
Receivable Days1425840474742
Inventory Days1527368678194
Payable Days19310194878066

Suven Pharmaceuticals Ltd Stock News

Suven Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Suven Pharma on 21-Nov-2024 13:56 is ₹1,272.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 13:56 the market cap of Suven Pharma stood at ₹32,571.6.
The latest P/E ratio of Suven Pharma as of 21-Nov-2024 13:56 is 131.8.
The latest P/B ratio of Suven Pharma as of 21-Nov-2024 13:56 is 14.76.
The 52-week high of Suven Pharma is ₹1,358.8 and the 52-week low is ₹578.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Suven Pharma is ₹914.5 ( Cr.) .

About Suven Pharmaceuticals Ltd

Suven Pharmaceuticals Limited, a company incorporated in November 2018, has become Wholly Owned Subsidiary of Suven Life Sciences Limited, effective February 2019. Suven Life Sciences Limited, post the Board meeting on February 5, 2019, announced demerger of Suven Life Sciences Limited into: Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs. Suven Pharmaceuticals Limited, the resultant entity, to continue the CRAMS business operations. The Scheme of Arrangement has since been approved by the National Company Law Tribunal (NCT), Hyderabad bench vide its order on 6th January 2020.

Pursuant to the Scheme of Arrangement between Suven Life Sciences Limited (‘Demerged Company’), Suven Pharmaceuticals Limited (‘Resulting Company’) and their respective shareholders and creditors, duly approved by the National Company Law Tribunal (NCLT), Hyderabad Bench, vide its Order dated 06th January, 2020, the Demerged Undertaking (as defined in the Scheme) of the Demerged Company has been demerged from Suven Life Sciences Limited and the same has been transferred to and vested in Suven Pharmaceuticals Limited with effect from 1st October, 2018, being the Appointed Date fixed in the said Scheme of Arrangement.

The Scheme, has become operative from the Appointed Date i.e., 1st October, 2018, but has become effective on 9th January, 2020 being the date on which certified copies of the Order of the NCLT, Hyderabad Bench sanctioning the Scheme was filed with the Registrar of Companies, Hyderabad, Telangana, both by the Demerged Company and Resulting Company.

Business area of the company

The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

Business segments

  • Pharmaceutical Solutions
  • Active Pharma ingredients
  • Intermediates
  • Formulations
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.